Preparation and evaluation of lipid-matrix nanocarrier co-delivery gene and sensibilizer to elevate docetaxel antitumor

doi:10.5246/jcps.2014.03.018

Abstract

Abstract:

It is a promising treatment strategy to use a nanoparticle-based drug delivery system for cancer patients, which can simultaneously deliver multiple drugs or genes in combination with therapy to induce synergistic effects and suppress drug resistanceto the tumor. In this study, cationic nanostructured lipid carriers (cNLC) for co-loading anionic small-interfering RNAs (siRNA) and chemotherapeutic docetaxel (DTX) were prepared from different cationic lipids based on particle distribution and loading efficiency. In order to increase the cNLC's positive targeting capacity, a novel peptide SP94 was bound to the surface of cNLC (SP94-cNLC). The cNLC showed good efficiency in loading siRNA and DTX. The SP94-cNLC revealed a better cytotoxicity compared with cNLC and Taxotere^®, indicating that SP94 could successfully enhance the internalization capacity of nanoparticles to the liver cancer cells. This new type of cNLC is a potential vehicle when using in co-delivery of chemotherapeuticsand siRNAs. The curcumin (CUR)/DTX co-delivery NLC could load both CUR and DTX in high efficiency and showed a sensibilization to DTX chemotherapy. The sensibilization was more obvious when it was used in the aggressive and resistant cancer cells. This CUR/DTX co-delivery system had good potential in treating cancer cells when chemotherapy drug showed little effect alone.

Key words: Co-delivery system, Docetaxel, Small-interfering RNAs, Curcumin, Preparation

CLC Number:

R994

Supporting:

Tingting Meng, Jingquan Li, Xianrong Qi. Preparation and evaluation of lipid-matrix nanocarrier co-delivery gene and sensibilizer to elevate docetaxel antitumor[J]. Journal of Chinese Pharmaceutical Sciences, DOI: 10.5246/jcps.2014.03.018.

References

[1] Liu, D.; Liu, F.; Liu, Z. Mol. Pharm. 2011, 8, 2291–2301.

[2] Moghimi, S.M.; Hunter, A.C.; Murray, J.C. FASEB J. 2005, 19, 311–330.

[3] Extra, J.M.; Rousseau, F.; Bruno, R.; Clavel, M.; Le Bail, N.; Marty, M. Cancer Res. 1993, 53, 1037–1042.

[4] Zhao, X.; Zhao, Y.; Geng, L.; Li, X.; Wang, X.; Liu, Z.; Wang, D.; Bi, K.; Chen, X. J. Chromatogr. B. 2011, 879, 3721–3727.

[5] Aagaard, L.; Rossi, J.J. Adv. Drug Deliv. Rev. 2007, 59, 75–86.

[6] Xue, H.Y.; Wong, H.L. Biomaterials. 2011, 32, 2662–2672.

[7] Kumar, L.D.; Clarke, A.R. Adv. Drug Deliv. Rev. 2007, 59, 87–100.

[8] Pirollo, K.F.; Chang, E.H. Cancer Res. 2008, 68, 1247–1250.

[9] Azmi, A.S.; Wang, Z.; Philip, P.A.; Mohammad, R.M.; Sarkar, F.H. Mol. Cancer Ther. 2010, 9, 3137–3144.

[10] Saad, M.; Garbuzenko, O.B.; Minko, T. Nanomedicine. 2008, 3, 761–776.

[11] Dong, D.W.; Xiang, B.; Gao, W.; Yang, Z.Z.; Li, J.Q.; Qi, X.R. Biomaterials. 2013, 34, 4849–4859.

[12] Chen, A.M.; Zhang, M.; Wei, D.; Stueber, D.; Taratula, O.; Minko, T.; He, H. Small. 2009, 5, 2673–2677.

[13] Xiong, X.B.; Lavasanifar, A. ACS Nano. 2011, 5, 5202–5213.

[14] Patel, N.R.; Pattni, B.S.; Abouzeid, A.H.; Torchilin, V.P. Adv. Drug Deliv. Rev. 2013, 65, 1748–1762.

[15] Maheshwari, R.K.; Singh, A.K.; Gaddipati, J.; Srimal, R.C. Life Sci. 2006, 78, 2081–2087.

[16] Xue, X.; Yu, J.L.; Sun, D.Q.; Zou, W.; Kong, F.; Wu, J.; Liu, H.P.; Qu, X.J.; Wang, R.M. Biomed. Prevent. Nutr.2013, 3, 173–176.

[17] Limtrakul, P.; Chearwae, W.; Shukla, S.; Phisalphong, C.; Ambudkar, S.V. Mol. Cell Biochem. 2007, 296, 85–95.

[18] Yin, H.; Guo, R.; Xu, Y.; Zheng, Y.; Hou, Z.; Dai, X.; Zhang, Z.; Zheng, D.; Xu, H. Acta Biochim. Biophys. Sin. 2012, 44, 147–153.

[19] Yallapu, M.M.; Jaggi, M.; Chauhan, S.C. Drug Discov. Today. 2012, 17, 71–80.

[20] Zhang, L.; Zhang, N. Int. J. Nanomed. 2013, 8, 2927.

[21] Liu, D.; Liu, Z.; Wang, L.; Zhang, N. Colloids Surf. B Biointerfaces. 2011, 85, 262–269.

[22] Pardeike, J.; Hommoss, A.; Müller, R.H. Int. J. Pharm. 2009, 366, 170–184.

[23] Lo, A.; Lin, C.T.; Wu, H.C. Mol. Cancer Ther. 2008, 7, 579–589.

[24] Zhang, Y.; Rong, Q.X.; Gao, Y.; Wei, L.; Maitani, Y.; Nagai, T. J. Control. Release. 2007, 117, 281–290.

[25] Gao, W.; Xiang, B.; Meng ,T.T.; Liu, F.; Qi, X.R. Biomaterials.2013, 34, 4137–4149.

[26] Carbone, C.; Tomasello, B.; Ruozi, B.; Renis, M.; Puglisi, G. Eur. J. Med. Chem. 2012, 49, 110–117.

[27] Kim, H.R.; Kim, I.K.; Bae, K.H.; Lee, S.H.; Lee, Y.; Park, T.G. Mol. Pharm. 2008, 5, 622–631.

[28] Yang, L.J.; Yang, T.; Jiang, J.; Xu, Z.Z.; Wang, J.J.; Zhang, Q. J. Chin. Pharm. Sci.2009, 18, 267–272.

[29] Melkonyan, H.; Sorg, C.; Klempt, M. Nucleic Acids Res. 1996, 24, 4356–4357.

[30] Fabbri, F.; Brigliadori, G.; Carloni, S.; Ulivi, P.; Vannini, I.; Tesei, A.; Silvestrini, R.; Amadori, D.; Zoli, W. J. Transl. Med. 2008, 6, 43.

[31] Maruyama, K. Adv. Drug Deliv. Rev. 2011, 63, 161–169.

[32] Goel, A.; Aggarwal, B.B. Nutr. Cancer. 2010, 62, 919–930.